Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study.
glioblastoma
multicenter study
overall survival
perfusion DSC
vascularity
Journal
Journal of magnetic resonance imaging : JMRI
ISSN: 1522-2586
Titre abrégé: J Magn Reson Imaging
Pays: United States
ID NLM: 9105850
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
16
07
2019
accepted:
19
09
2019
pubmed:
28
10
2019
medline:
15
5
2021
entrez:
27
10
2019
Statut:
ppublish
Résumé
Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a heterogeneous and abnormal vascularity. Subtypes of vascular habitats within the tumor and edema can be distinguished: high angiogenic tumor (HAT), low angiogenic tumor (LAT), infiltrated peripheral edema (IPE), and vasogenic peripheral edema (VPE). To validate the association between hemodynamic markers from vascular habitats and overall survival (OS) in glioblastoma patients, considering the intercenter variability of acquisition protocols. Multicenter retrospective study. In all, 184 glioblastoma patients from seven European centers participating in the NCT03439332 clinical study. 1.5T (for 54 patients) or 3.0T (for 130 patients). Pregadolinium and postgadolinium-based contrast agent-enhanced T We analyzed preoperative MRIs to establish the association between the maximum relative cerebral blood volume (rCBV Uniparametric Cox regression; Kaplan-Meier test; Mann-Whitney test. The rCBV The rCBV 3 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2020;51:1478-1486.
Sections du résumé
BACKGROUND
Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a heterogeneous and abnormal vascularity. Subtypes of vascular habitats within the tumor and edema can be distinguished: high angiogenic tumor (HAT), low angiogenic tumor (LAT), infiltrated peripheral edema (IPE), and vasogenic peripheral edema (VPE).
PURPOSE
To validate the association between hemodynamic markers from vascular habitats and overall survival (OS) in glioblastoma patients, considering the intercenter variability of acquisition protocols.
STUDY TYPE
Multicenter retrospective study.
POPULATION
In all, 184 glioblastoma patients from seven European centers participating in the NCT03439332 clinical study.
FIELD STRENGTH/SEQUENCE
1.5T (for 54 patients) or 3.0T (for 130 patients). Pregadolinium and postgadolinium-based contrast agent-enhanced T
ASSESSMENT
We analyzed preoperative MRIs to establish the association between the maximum relative cerebral blood volume (rCBV
STATISTICAL TESTS
Uniparametric Cox regression; Kaplan-Meier test; Mann-Whitney test.
RESULTS
The rCBV
DATA CONCLUSION
The rCBV
LEVEL OF EVIDENCE
3 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2020;51:1478-1486.
Substances chimiques
Contrast Media
0
Banques de données
ClinicalTrials.gov
['NCT03439332']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1478-1486Informations de copyright
© 2019 International Society for Magnetic Resonance in Medicine.
Références
Louis N, Perry A, Reifenberge RG, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131:808.
Gately L, McLachlan SA, Dowling A, et al. Life beyond a diagnosis of glioblastoma: A systematic review of the literature. J Cancer Surviv 2017;11:447-449.
Bae S, Choi YS, Chang JH, et al. Radiomic MRI phenotyping of glioblastoma: Improving survival prediction. Radiology 2018;289:797-798.
Akbari H, Macyszyn L, Da X, et al. Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity. Radiology 2014;273:503.
Soeda A, Hara A, Kunisada T, et al. The evidence of glioblastoma heterogeneity. Sci Rep 2015;5:1-6.
Weis SM, Cheresh DA. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 2011;17:1359-1365.
De Palma M, Biziato D, Petrova TV, et al. Microenviromental regulation of tumour angiogenesis. Nat Rev Cancer 2017;17:13.
Jain R, Poisson LM, Gutman D, et al. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: Focus on the non-enhancing component of the tumor. Radiology 2014;272:484-493.
Jensen RL, Mumert ML, Gillespie DL, Kinney AY, Schabel MC, Salzman KL. Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol 2014;16:280-291.
Fuster-Garcia E, García-Gómez JM, et al. Imaging biomarkers. In: Martí-Bonmatí L, Alberich-Bayarri A, eds. Development and clinical integration. Cham, Switzerland: Springer International Publishing. 2017;181-194.
Demerath T, Simon-Gabriel CP, Kellner E, et al. Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype. Neuroradiol J 2017;30:36-47.
Jena A, Taneja S, Gambhir A, et al. Glioma recurrence versus radiation necrosis: Single-session multiparametric approach using simultaneous O-(2-18f-Fluoroethyl)-L-tyrosine PET/MRI. Clin Nucl Med 2016;41;228-236.
Price SJ, Young Adam MH, Scotton William J, et al. Multimodal MRI can identify perfusion and metabolic changes in the invasive margin of glioblastomas. J Magn Reson Imaging 2016;43;487-494.
Chang Y-CC, Ackerstaff E, Tschudi Y, et al. Delineation of tumor habitats based on dynamic contrast enhanced MRI. Sci Rep 2017;7:9746.
Cui Y, Tha KK, Terasaka S, et al. Prognostic imaging biomarkers in glioblastoma: Development and independent validation on the basis of multi-region and quantitative analysis of MR images. Radiology 2016;278:546-553.
Juan-Albarracín J, Fuster-García E, Pérez-Girbés, et al. Glioblastoma: Vascular habitats detected at preoperative dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging predict survival. Radiology 2018;287:944-954.
Fuster-García E, Juan-Albarracín J, García-Ferrando GA, et al. Improving the estimation of prognosis for glioblastoma patients by MR based hemodynamic tissue signatures. NMR Biomed 2018:25-32.
Abramson RG, Burton KR, Yu JJ, et al. Methods and challenges in quantitative imaging biomarker development. Acad Radiol 2015;22:26-27.
O'Connor JPB, Aboagye EO, Adams JE, et al. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 2016;14:174-177.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intra cranial mass lesions: Interobserver and intra observer reproducibility study. Radiology 2002;224:798-802.
Schnack HG, van Haren NEM, Hulshof Pol HE, et al. Reliability of brain volumes from multicenter MRI acquisition: A calibration study. Hum Brain Mapp 2004;22:312-320.
De Guio F, Jouvent E, Biessels GJ, et al. Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. J Cereb Blood Flow Metab 2016;36:1319-1337.
Liu TT, Achrol AS, Mitchell LA, et al. Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. Neuro Oncol 2017;19:1000-1002.
Hirai T, Murakami R, Nakamura H, et al. Prognostic value of perfusion MR imaging of high-grade astrocytomas: Long-term follow-up study. Am J Neuroradiol 2008;29:1506-1509.
Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: A method for predicting response to angiogenic chemotherapy by using MR perfusion imaging - Pilot study. Radiology 2010;255:622-628.
Hambardzumyan D, Bergers G. Glioblastoma: Defining tumor niches. Trends Cancer 2015;1:252-265.
Artzi M, Bokstein F, Blumenthal DT, et al. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: A longitudinal MRI study. Eur J Radiol 2014;83:1250-1256.
Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:99-109.